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Abstract
Background: Beyond survival of nowadays >80%, modern childhood cancer treatment strives to preserve long-term health
and quality of life. However, the majority of today’s survivors suffer from short- and long-term adverse effects such as
cardiovascular and pulmonary diseases, obesity, osteoporosis, fatigue, depression, and reduced physical fitness and quality of
life. Regular exercise can play a major role to mitigate or prevent such late-effects. Despite this, there are no data on the
effects of regular exercise in childhood cancer survivors from randomized controlled trials (RCTs). Primary outcome of the
current RCT is therefore the effect of a 12-months exercise program on a composite cardiovascular disease risk score in
childhood cancer survivors. Secondary outcomes are single cardiovascular disease risk factors, glycaemic control, bone health,
body composition, physical fitness, physical activity, quality of life, mental health, fatigue and adverse events (safety).
Methods: A total of 150 childhood cancer survivors aged ≥16 years and diagnosed ≥5 years prior to the study are recruited
from Swiss paediatric oncology clinics. Following the baseline assessments patients are randomized 1:1 into an intervention
and control group. Thereafter, they are seen at month 3, 6 and 12 for follow-up assessments. The intervention group is
asked to add ≥2.5 h of intense physical activity/week, including 30 min of strength building and 2 h of aerobic exercises. In
addition, they are told to reduce screen time by 25%. Regular consulting by physiotherapists, individual web-based activity
diaries, and pedometer devices are used as motivational tools for the intervention group. The control group is asked to keep
their physical activity levels constant.
Discussion: The results of this study will show whether a partially supervised exercise intervention can improve
cardiovascular disease risk factors, bone health, body composition, physical activity and fitness, fatigue, mental health and
quality of life in childhood cancer survivors. If the program will be effective, all relevant information of the SURfit physical
activity intervention will be made available to interested clinics that treat and follow-up childhood cancer patients to
promote exercise in their patients.
Trial registration: Prospectively registered in clinicaltrials.gov [NCT02730767], registration date: 10.12.2015.
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Background
Thanks to improvements in diagnosis, treatment and sup-
portive care of childhood cancer patients, 5-year survival
rates have increased drastically since the 1960s and
reached 81% in the last decade in Europe [1, 2], including
Switzerland [3]. However, childhood cancer survivors
(CCS) are at risk to develop a series of physical or psycho-
logical late-effects, either directly as a result of the tumour
and the aggressive treatments received, or secondary due
to an unfavourable lifestyle [4–6]. The authors of a recent
study estimated that 96% of CCS suffer from any chronic
health condition and 81% from a serious or life-
threatening chronic disease by the age of 45 years [7].
These late-effects shift the focus of modern childhood
cancer treatment and research from pure survival to long-
term functionality, health and quality of life [8].
Based on evidence from the general population or adult
cancer survivors, we can hypothesise that regular physical ac-
tivity has the potential to decrease the survivors’ risk for late-
effects, such as cardiovascular diseases (CVD) [9–11], stroke
[11, 12], second cancers [11, 13], obesity [11, 14], dyslipidae-
mia [15, 16], insulin resistance and diabetes mellitus [11, 17],
osteoporosis [18–21], depression [22, 23], and cognitive de-
cline [24, 25]. Despite these encouraging findings on benefits
of exercise in various populations, specific studies on physical
activity interventions in adult or adolescent survivors of
childhood cancer aiming to reduce late-effects and increase
physical activity are scarce. Small controlled exercise inter-
ventions over 2–4 months have shown beneficial effects on
fatigue [26], metabolic risk factors and fitness [27], but to
date no randomized controlled studies have been published.
Furthermore, traditional physical activity interventions
in any field usually focus on specific types of exercises
(such as strength training, tai chi, etc.) and participants
are invited several times per week to join exercise sessions
[28]. The problem of such a supervised and standardized
approach is that the increase in physical activity is often
not maintained by individuals after the intervention has
ended and does therefore not lead to a sustained change
in their behaviour [28, 29]. Our study is novel in applying
an individual and motivational feedback-based approach
with a personalized exercise counselling and program em-
bedded in each participant’s daily life. Such an interven-
tion may have a higher potential to result in a lasting
behaviour change towards an active lifestyle and therefore
ameliorate physical and psychological late-effects.
Methods/design
This study protocol is written in accordance with the SPIRIT
guidelines [30] (see the SPIRIT Checklist in Additional file 1).
Study objectives
The primary objective of the proposed study is to evaluate
the effect of a partially supervised and personalized physical
activity program on the cardiovascular disease (CVD) risk
of adolescent and adult survivors of childhood cancer in a
randomized controlled trial. Secondary objectives are to
assess the effect of the physical activity program on single
CVD risk factors, glycaemic control, bone health, body
composition, physical fitness, physical activity, quality of
life, mental health, fatigue and adverse events (safety).
Primary outcome
The primary outcome of the randomized controlled trial
(RCT) is defined as the change in a composite CVD risk
score [31, 32] from baseline to 12 months in the participants
of the intervention group compared to the participants of
the control group. The composite score is based on the as-
sumption that a physical activity intervention shall have
overall beneficial effects on the cardio-metabolic risk, affect-
ing most if not all components of the metabolic syndrome.
We chose a composite CVD risk score because the preva-
lence of single components of the metabolic syndrome is
low in adolescents and young adults. A longitudinal study
showed that a clustered score in adolescents predicted
metabolic syndrome in adulthood [33] and was sensitive to
change by a physical activity intervention in youth [34]. The
composite CVD risk score will be calculated by averaging
the z-scores based on gender- and age-specific external
references of all components of the metabolic syndrome,
including waist circumference, blood pressure, homeostatic
model assessment insulin resistance [HOMA-IR], inverted
high density lipoprotein cholesterol, triglycerides and
cardiorespiratory fitness [32, 34–39].
Secondary outcomes
Secondary outcomes are differences in change between the
intervention and control group from baseline to 6 months
for the composite cardiovascular disease risk score, and
from baseline to 6 and 12 months for the single CVD risk
factors, glycaemic control, bone health, body composition,
physical fitness, physical activity, quality of life, mental
health, fatigue and adverse events (safety). Additional file 2:
Table S1 lists all assessed outcome variables.
Study design
This study is a single-centre RCT including childhood can-
cer survivors from various paediatric oncology clinics of
Switzerland. Control and intervention arms run parallel
(Fig. 1). Assessments are performed at baseline (T0) and
after three (T3), six (T6), and 12 (T12) months. The assess-
ments at T0, T6 and T12 comprise of two visits (a and b,
respectively) in the study centre, 14 days apart, and T3 of
one visit. Randomization is performed after the first visit of
T0 (T0a) (Additional file 2: Table S1, Fig. 1). A motivational
interview for the intervention group is performed at the
second visit of T0 (T0b). After the intervention period, con-
trols are offered a similar personalized exercise programme
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without long-term coaching (see paragraph on physical
activity intervention). Eligible participants are contacted,
informed and, if consenting, enrolled into the study (see
paragraph on recruitment) until we reach the pre-defined
number of participants.
Ethics
The study was approved by the Swiss Ethics Committee on
research involving humans (Ethikkommision Nordwest- und
Zentralschweiz [EKNZ]). Informed Consent as documented
by signature is obtained from each survivor prior to partici-
pation in the study. Data protection is assured by pseudony-
mization and can only be decrypted by study personnel
involved in this research.
Study population / inclusion criteria
Eligible participants are identified by the Swiss Childhood
Cancer Registry (SCCR) [40, 41]. SURfit includes CCS aged
<16 years at diagnosis, diagnosed with a cancer classifiable
according to the International Classification of Childhood
Cancer (ICCC-3) [42] or Langerhans Cell Histiocytosis, who
were diagnosed and treated at a clinic of the Swiss Paediatric
Oncology Group (SPOG), survived ≥5 years since primary
cancer diagnosis or any subsequent cancer event (relapse or
2nd tumour), and, are aged ≥16 years at baseline (T0a) of
the study. Participants have to agree that they will commit to
the conditions of their study group allocation prior to the
allocation and independent of the allocation.
The presence of any of the following criteria, assessed at
baseline (T0a), leads to exclusion of the participant:
participation in another clinical trial, inability to exercise or
exercise potentially harmful, pregnant or breast feeding,
cardiac arrhythmias under exercise, diagnosis of diabetes
<3 months previously, detection or presence of a clinical
condition that needs immediate treatment, planned surgeries
within the subsequent 12 months that interfere with physical
exercising, major musculoskeletal injuries/fractures <2months
previously, change in medication that interfere with the pa-
rameters of the CVD risk score < 1 month previously, >4 h of
reported vigorous physical activities per week, or, inability to
follow the procedures and understand the intervention and
assessments of the study, e.g. due to cognitive impairment,
language problems, or psychological disorders.
Recruitment
Eligible patients are contacted with an information letter
from their former treating hospital including a short study
information brochure. Interested survivors then receive the
detailed patient information of the study and the informed
consent. Survivors decide upon this information whether
or not they want to participate in the study. A study hotline
or the responsible investigator can be contacted to clarify
remaining questions about the study. All survivors who do
not react to the study invitation are followed-up by a phone
call and asked about their interest in the study. Survivors
who decide to participate are invited for the baseline assess-
ment where final decision upon eligibility is made and the
informed consent is obtained.
We record the reasons for non-participation of each
contacted survivor who does not want to participate. In
addition, basic information on demographics and clinical
factors are available from the SCCR on non-participants.
This will allow us to get information on the representa-
tiveness of the participants in the study.
Fig. 1 SURfit study design. Shows the general design and procedure of the SURfit study. All visits of T0, T3, T6 and T12 are at the University Children’s
Hospital Basel (UKBB) including a visit at the Bone Research Unit of the University Hospital Basel (USB) to perform the DXA and pQCT scans (T0a and
T12a). After one year of trial, participants of the control intervention who wish to, can receive the same personalized exercise counselling with
motivational tools but no personal follow-up coaching. Participants of the intervention group will hopefully continue their training without supervision
of the study team but still having access to the motivational tools of the study. Abbreviations: DXA, dual x-ray absorptiometry; mt, months; oGTT, oral
glucose tolerance test; pQCT, peripheral quantitative computed tomography; SCCR, Swiss Childhood Cancer Registry; T0a, initial baseline visit; T0b,
second visit for baseline assessments; T3, assessment after 3 months; T6a and T6b, first and second visit of assessments after 6 months; T12a and T12b,
first and second visit of assessments after 12 months
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Randomization
To ensure high quality randomization and even distribution
of important prognostic factors among the intervention and
the control group, a web-based minimization randomization
approach (Randomizer: Institute for Medical Informatics,
Statistics and Documentation, Medical University of Graz,
Austria; available at www.randomizer.at) is used for the 1:1
allocation of participants into the two study arms [43]. We
include gender and four categories according to the initial
cancer diagnosis (leukaemia and lymphoma; CNS tumours;
bone tumours and soft tissue sarcomas; other diagnoses) as
grouping variables in the randomization. An external
collaborator who is independent of the patient recruitment
and enrolment process runs the randomization and
treatment allocation (Additional file 2: Table S1).
Measurements
Additional file 2: Table S1 gives an overview of the measure-
ments and procedures at each time point of the study;
Additional file 3 summarizes the measurements and respect-
ive methods used. Standard operating procedures (SOP)
were developed for each measurement prior to the beginning
of the study to reach a high level of standardisation and reli-
ability. All assessors were extensively trained for the specific
methods including pilot assessments prior to the study.
Regular internal inspections of the assessments are carried
out to maintain high methodological quality.
Study data are collected and managed using REDCap
electronic data capture tools hosted at the Clinical Trials
Unit, University of Bern [44]. All self-reported question-
naires are filled in by the participants directly in the RED-
Cap database with a personal login during the study visits.
All data entries are double-checked for consistency, errors
and completeness by a data monitor. The data monitor, a
member of the study team but independent of all the
assessments, notifies any problem encountered back to
the assessor using the specified feature in REDCap.
Bloods
Fasted blood samples are taken in the morning after an
overnight fast of at least 8 h. Glucose and glycated haemo-
globin (HbA1c) are analysed within a few hours after sam-
pling at the laboratory of the University Hospital of Basel.
The other parameters assessed in the blood serum and
plasma are centrifuged, divided into 1.0 ml aliquots and
stored at −70 °C to be analysed at a later time point when
a test kit can be completed at a the certified laboratory of
the Endonet and Bone Research Unit, Basel.
Cardiovascular disease risk
Blood pressure
Systolic and diastolic blood pressure is measured in sitting
position on the left upper arm after at least 5 min rest using
an automated oscillography (DINAMAP® ProCare [GE
Medical Systems, Tampa, Florida, USA]). Based on the rec-
ommendations of the American Heart Association, the
mean of two readings with a one-minute interval between
them are recorded [45]. If the difference between the two
readings is >5 mmHg, another two readings are taken [45].
Anthropometry
Standing height and weight are taken by standard proce-
dures, barefoot and in underwear. Height is determined to
the nearest 0.5 cm, weight is determined to the nearest
0.1 kg. Waist circumference is measured with a medical
measuring tape to the nearest 0.5 cm. It is measured at the
narrowest part of the torso (the middle between lower rib
arch and spina iliaca) in relaxed, standing position at the
end of expiration [46, 47]. Skinfold (SF) thickness is
measured in triplicate to the nearest 0.2 mm with a
Harpenden calliper (Harpenden Skinfold Calliper [Baty
International, West Sussex, United Kingdom]) on the right
body site at sites over triceps, biceps, subscapular and
suprailiacal based on standard procedures [48, 49]. The
sum of the four SF (each averages of the three readings) is
taken to calculate absolute [kg] and relative [%] body fat by
a formula validated against underwater weighing [49]. With
this formula, body fat can be estimated with 3–5% error
[49]. Lean body mass is derived from total body mass and
body fat. Furthermore, percent fat mass, absolute fat mass
and lean body mass (total body and regional) are estimated
by whole body dual x-ray absorptiometry (DXA) using a
Hologic Discovery densitometer (Hologic, Bedford MA,
USA) [50, 51]. Body composition estimation from DXA
scan shows good precision with a 2–3% coefficient of
variation (CV) [52]. Muscle cross-sectional area (CSA)
[cm2 and z-scores] at proximal tibia and radius is assessed
using peripheral Quantitative Computed Tomography
(pQCT, Stratec XCT 2000 scanner; Stratec Medical
Pforzheim, Germany). Muscle CSA is obtained by subtract-
ing fat CSA and bone CSAs from the CSA of the total limb.
Precision error for muscle CSA determination of the calf
by pQCT was found to be between 0.5%–4.1% [53–55].
Glycaemic control
Serum levels for insulin and C-peptide are determined by
chemiluminescent enzyme immunoassays (ECLIA). The re-
producibility based on the Elecsys 2010 Analyzer is 2.5–
2.8% for insulin and 1.8–5.0% for C-peptide, respectively.
Glucose is measured by the hexokinase method (Modular),
consisting of a control unit, a core unit and an analytic ISE
unit (E-module). Insulin resistance (IR) is estimated by cal-
culating homeostasis model assessment (HOMA-IR) index
(fasting serum insulin [μU/ml] × fasting plasma glucose
[mmol/l)/22.5]) [56]. HbA1c is measured by a high effi-
ciency fluid chromatography HPLC (VG8). In addition, 2 h
75 g oral glucose tolerance test (oGTT) after an overnight
(≥8 h) fast is done to assess insulin resistance [57–59].
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Blood lipids
Total cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol and triglyc-
erides are measured by standard method on an auto-
analyser (COBAS Integra 800; Roche Diagnostics, Basel,
Switzerland). Intra-assay and inter-assay CVs are between
1.6–2.2% for total cholesterol, 2.4–3.6% for HDL, 0.7–2.1%
for LDL, and 1.1–3.7% for triglycerides, respectively.
Bone health
Bone mineral content and density
Bone mineral content (BMC, g), bone area (BA, cm2) and
areal bone mineral density (aBMD, g/cm2) are measured
at the lumbar spine, femoral neck and hip by DXA using a
Hologic Discovery densitometer (Hologic, Bedford MA,
USA) according to existing guidelines [60]. For aBMD
evaluation at the lumbar spine, mean aBMD data of verte-
bral bodies L1 to L4 are reported unless vertebral bodies
showing artefacts need to be excluded. A single densitom-
eter is used throughout the study. In a previous study, the
CV of individual measurements was 1.1% for the spine,
1.4% for the femoral neck, 1.9% for the trochanteric re-
gion, and 1.1% for the total hip [61]. The total radiation
exposure of a DXA scan is 3–6 μSv.
Trabecular bone score (TBS)
Measurement is performed using spine DXA files with the
TBS iNsight Software (version 1.8; Med-Imaps, Pessac).
The software uses the antero-posterior spine raw image(s)
from the densitometer, including the BMD region of inter-
est and edge detection so that the TBS calculation is per-
formed over exactly the same region of interest as the
aBMD measurement. It assesses the heterogeneity of the
areal density, with a higher heterogeneity implying poorer
trabecular connectivity. Short-term reproducibility (CV)
for TBS is reported to be 2.1% and 1.7% for spine aBMD
in 92 individuals with repeat spine DXA scans performed
within 28 days [62, 63].
Vertebral fracture assessment (VFA)
Is an established, low radiation method for detection of
prevalent vertebral fractures using DXA [64]. Lateral spine
scans are performed simultaneously with aBMD measure-
ments using the Hologic Discovery densitometer. Spine
fractures are classified using the standard semi quantitative
scoring system of Genant and colleagues [65]. This scoring
system differentiates three fracture grades based on the
height reduction of the affected vertebral body (grade 1:
20–25%; grade 2: 25–40%, grade 3:>40%) [65].
Bone architecture & strength
Volumetric bone density (vBMD), bone mass, and bone
geometry is measured using pQCT (Stratec XCT 2000
scanner; Stratec Medical Pforzheim, Germany) at the distal
epiphysis and diaphysis of the non-dominant lower leg and
lower arm. We will assess bone total CSA in mm2 at the
epiphyseal and diaphyseal sites, cortical CSA (excluding the
medullary CSA) in mm2 at the diaphyseal sites, total and
trabecular vBMD in mg/cm3 at the epiphyseal sites, and
cortical BMD in mg/cm3 at the diaphyseal sites [66, 67].
Absolute values are transformed in z-scores based on refer-
ence values [68, 69].
Quantitative computed tomography measures attenuation
of x-rays projected through the limb at one-degree steps
covering 180 degrees, resulting in an image of the cross-
section of the limb. The slice thickness of 2 mm allows a
three-dimensional (volumetric) assessment of bone density.
X-ray attenuation is linearly transformed into hydroxyapatite
(HA) densities. Unlike some other pQCT scanners, the
Stratec XCT 2000 is calibrated with respect to water which
is set at 60 mg HA, so that fat results in 0 mg HA [70]. HA
equivalent densities are automatically calculated from the
attenuation coefficients by employing the manufacturer’s
phantom which itself is calibrated with respect to the
European Forearm Phantom (EFP; QRM, Erlangen,
Germany) [70]. The effective radiation dose is 0.2 μSv per
scan and per scout view as indicated by the manufacturer.
Radius bone length is set equal to ulnar length, which is
measured to the nearest 5 mm with a measuring tape by
palpation of the olecranon and the ulnar styloid. Tibia
length is measured from the medial knee joint cleft to the
end of the medial malleolus. A scout view of the distal end
of tibia and radius is performed and the automated detec-
tion algorithm provided by the manufacturer is used to
place the reference line at the distal bone end. Two scans
are performed for each of radius and tibia: one at 4% of
total bone length measured from the reference line of the
scout view in the distal epiphysis, and one at 66% of total
bone length in the proximal part of the diaphysis. A
reproducibility study based on 9 subjects with 4 repeated
measurements defined the smallest detectable differences
(1.96 × Standard Deviation [SD]) to be 4.74 and 3.92 mg/
cm3 for trabecular vBMD at the radius and tibia, respect-
ively, and 11.68 and 5.39 mg/cm3 for total vBMD at the
radius and tibia, respectively [71].
Bone metabolism and hormones
Biomarkers of bone metabolism provide a quantitative
measure of the relationship between bone deposition and
resorption. Measuring the balance between deposition and
resorption in relation is the basis of explaining change in
BMD over time and can be taken as determinant of BMD
change. The following biochemical markers of bone turn-
over are assessed: a) bone formation markers: bone-specific
alkaline phosphatase (BAP), osteocalcin (OC), N-terminal
propeptide of type I procollagen (PINP); b) bone resorption
markers: C-terminal telopeptide of type I collagen (CTX).
Serum BAP (IDS-iSYS Ostase BAP) as well as 25-hydroxy-
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vitamin D3 (IDS-iSYS 25-Hydroxy Vitamin D) will be de-
termined using an enzyme-immunoassay (EIA) on the IDS-
iSYS (Immunodiagnostic Systems, Frankfurt/Germany).
The intra- and inter-assay variations are <9% for BAP [72,
73], and 3.6% and 16.9% for 25-hydroxy-vitamin D3 [74,
75], respectively. The parameters beta-CrossLaps (CTX),
N-MID-Osteocalcin, PINP and intact parathyroid hormone
(iPTH) are measured in serum with ECLIA on the auto-
mated analyser Elecsys 2010 (Roche Diagnostics, Rotkreuz,
Switzerland) [76, 77]. The intra- and inter-assay variations
are 2.4–7.2% for CTX, 1.1–5.9% for OC, 1.7–4.0% for PINP,
and 1.7–5.5% for iPTH, respectively [61]. Uncarboxylated
OC (ucOC) is measured after previous incubation of serum
samples with hydroxyapatite (5 mg/ml) to separate out
carboxylated OC (cOC) from the ucOC as previously
described [78]. The ucOC in the supernatant is measured
using the same assay as for total osteocalcin and will be re-
ported as a concentration and as a fraction of the total [79].
Further hormone analyses including thyroid-stimulating
hormone (TSH), free thyroxine (fT4), gonadotropins
(luteinizing hormone [LH], follicle-stimulating hormone
[FSH]), estradiol (E2), total testosterone (TT) and cortisol
will be carried out using ECLIA on the automated analyser
COBAS e411 (Roche Diagnostics, Rotkreuz, Switzerland).
The intra- and inter-assay variations are 1.5–8.7% for TSH,
1.8–7.6% for fT4, 0.8–5.2% for LH, 1.8–5.3% for FSH, 2.4–
11.9% for E2, 1.2–8.4% for TT, and 1.1–1.6% for cortisol,
respectively [80].
Insulin like growth factor 1 (IGF-1) and insulin like growth
factor binding protein 3 (IGF-BP3) are determined using
ECLIA on the IDS-iSYS (Immunodiagnostic Systems, Frank-
furt/Germany). The intra- and inter-assay variations are 6.0%
and 9.8% for IGF-1, and 7.9% and 15.5% for IGF-BP3, re-
spectively [81]. All assays are performed in duplicate by using
the same biomarker kit, and the mean value will be recorded.
Nutrition
To correctly interpret bone health of the subjects, the
relevant parameters like calcium intake [mg/day], protein
intake [g/day] and vitamin D (supplement intake, sun ex-
posure and nutrition) are also assessed with standardized
and validated self-reported questionnaires [82, 83].
Physical fitness
Aerobic fitness
The participants complete a continuous incremental cycling
test to volitional exhaustion following the step protocol pro-
posed by Godfrey and colleagues [84] in accordance to the
international guidelines for exercise testing [85, 86]. Work
rate is increased every minute by 20 W with an initial load of
20 W. At each visit, a 12-lead electrocardiogram (ECG, Schil-
ler CS-200, Schiller AG, Baar, Switzerland) at rest is per-
formed to rule out relevant arrhythmias and other
pathologies that may pose a risk to the patient during the
cycling test and/or intervention. All participants are tested
using a calibrated cycle ergometer (Ergospirometrie-System
CS-200 and SCHILLER ERG 911S Plus cycle ergometer
[SCHILLER AG], Baar, Switzerland) and metabolic cart (LF8
PowerCube®-Ergo Gas-Analysator [Ganshorn Medizin Elec-
tronic], Niederlauer, Germany). The metabolic cart is cali-
brated before each exercise test with two gases of known
concentrations. Peak oxygen uptake (VO2peak) is deter-
mined by the highest VO2 averaged over 30s during the test.
Peak performance (Wpeak) is defined as the power main-
tained over the final 1-min stage of the test plus 5 W for
each fulfilled 15 s bout of the non-finished stage. Maximal
aerobic power and VO2peak will be expressed in percent of
predicted [87]. Electrocardiography using chest leads and
oxygen saturation measured at the finger (Masimo SET-
Monitor Radical-7, [Masimo Corporation], Irvine, USA) are
used to monitor the participant throughout the test for safety
reasons and to determine maximal heart rate and desatur-
ation under exercise. The test is terminated according to
existing guidelines [86]. Blood pressure and Borg Rating of
Perceived Exertion (RPE) are assessed at the end of each
stage [88, 89]. In addition, heart rate, blood pressure and
Borg RPE are assessed 1, 2, and 3 min post exercise to assess
recovery as a marker of physical fitness [90].
Muscular strength
To assess muscular strength of the lower body, the 1-min
sit-to-stand (STS) test is performed [91, 92]. The participants
perform one test trial at least 20 min before the final test.
The number of repetitions of standing up and sitting down
from a chair in the final test is recorded. In addition, Borg
RPE is assessed at the end of the test [88, 89]. The test is
performed on a height adjustable chair to ensure a 90° knee
angle. The 1-min STS test showed high reliability and good
criterion related validity with other exercise capacity tests
such as the 6-min walk test or stair climbing [93–96]. Exist-
ing population-based reference values from Switzerland will
help to identify subjects with decreased lower body muscular
strength and endurance [91].
Upper body strength is assessed through a handgrip
strength test using the JAMAR Hydraulic Hand Dynamom-
eter (Lafayette Instrument®, Lafayette, USA). The JAMAR
dynamometer was validated in several studies and is
regarded as the gold standard in measuring handgrip
strength [97]. The dynamometer assesses force in kg (0–
90 kg) to the nearest 2 kg. Hand grip strength is measured
according to the American Society of Hand Therapists
(ASHT) recommendations in a sitting position on a height
adjustable chair with the dynamometer resting on a table in
front of the subject [98]. Each hand is measured 3 times,
with alternating sides, starting with the right hand and one
minute breaks between measurements. A 1-min break is
described as sufficient in the literature in order to yield
consistent values [99].
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Physical activity
Pedometer
Participants wear a pedometer (Fitbug Air®, Fitbug,
London, United Kingdom) between the two visits of T0,
T6 and T12, to count number of daily steps (divided into
overall steps and aerobic steps) [100]. The steps per day of
the preceding 14 days are stored in the device and entered
into the REDCap database when the participant returns
the device at the second visit.
In addition, participants of the intervention group will
wear a pedometer and record their daily steps through-
out the entire study period (see paragraph on physical
activity intervention).
Accelerometer
Physical activity (PA) is assessed by accelerometer
(ActiGraph, Pensacola, Florida, USA) which will be worn
on the right hip during at least 7 days between the two
visits of T0, T6 and T12. The device measures accelerations
of ±6 G. The sample rate of the accelerometer will be set to
measure raw signals at 100 Hz. These are then translated
into either metabolic energy equivalents of no, light, mod-
erate and vigorous physical activities to estimate the effect
on the metabolic outcomes or in cumulative impacts per
day for the bone outcomes. Data are included if at least four
full days (including at least one weekend day) with a mini-
mum of 10 h are measured [101]. Participants are asked to
wear the accelerometer also at night to capture sleeping
time. Validity of accelerometer is good with correlation co-
efficients of 0.65 between accelerometer assessed metabolic
energy equivalents and indirect calorimetry [102], and 0.74
between accelerometer impact loading and ground reaction
forces by force plates [103]. For metabolic outcomes, over-
all PA will be expressed as total PA (total counts), average
PA in counts/min, as well as time (min/d) sedentary and in
light, moderate and vigorous PAs according to proposed,
previously published cut-off levels [101, 102, 104]. For bone
outcomes, impact loading will be expressed as cumulative
impacts per day (n/day) >2, 3, 4, 5 and 6 G, respectively.
Less than 100 impact loadings >3.9 G per day were shown
to be effective to increase bone mineral density in premen-
opausal women with higher effects in those with low base-
line values [105]. Such a level is reached with jogging, fast
running and jumping activities.
Questionnaire
The Seven-Day Physical Activity Recall questionnaire
(PAR), the Exercise Motivations Inventory (EMI-2) and a
self-constructed questionnaire including items of the Lipid
Research Clinics questionnaire (LRC) are used to assess the
time individuals engage in physical activity, their reasons
for exercising, and type and time of sports. The PAR as-
sesses the time an individual engaged in moderate, hard,
very hard activities and sleep during the 7 days prior to the
assessment [106]. The PAR was validated in several studies
against objective measures of physical activity and showed
satisfying psychometric properties in different populations
such as children and adults [106–109]. The EMI-2 is a vali-
dated scale to measure an individual’s reason for exercising.
It comprises of 44 items reflecting 12 dimensions including
stress management, weight management, recreation, social
recognition, enjoyment, appearance, personal development,
affiliation, ill-health avoidance, competition, fitness and
health pressures [110, 111]. The self-constructed question-
naire includes items on type and time of current sports and
questions from the validated LRC [112].
Quality of life and mental health
Health related quality of life
Is assessed using the Short Form-36 (SF-36) [113, 114].
This instrument is validated and has been successfully used
in samples of long-term CCS [115–119]. It consists of 36
questions that can be summarized into eight scales: physical
functioning, role limitation due to physical health (role
limitation physical), bodily pain, general health perception,
energy & vitality, social functioning, role limitation due to
emotional problems (role limitation emotional), and mental
health. The eight scales can be further aggregated into a
Physical Component Summary (PCS) and a Mental Com-
ponent Summary (MCS) [114]. We will convert raw scores
into T-scores (mean = 50, SD = 10, range 0–100) according
to age- and sex-stratified norm data from a public use-file
of the German Federal Survey (N = 6964) because no Swiss
data of the SF-36 are available [113].
Fatigue and actual well-being
Is assessed with a Visual Analogue Scale (VAS) and the
Checklist Individual Strength (CIS). A VAS for fatigue and
well-being is designed to measure these characteristics,
which are believed to range across a continuum of values
and cannot easily be measured directly. Operationally, the
VAS is a horizontal line, 100 mm in length, anchored by
two word descriptors at each end. In our study, the
descriptors will range from ‘not tired at all’ to ‘completely
exhausted’ for fatigue and from ‘feeling absolutely
miserable’ to ‘perfect well-being’ for well-being. The CIS is
a validated 20-item questionnaire, that is designed to meas-
ure four aspects of fatigue that may have been experienced
during the previous 2 weeks, i.e. severity of fatigue (8
items), concentration (5 items), motivation (4 items) and
physical activity (3 items) [26, 120, 121]. Each item is scored
on a 7-point Likert scale. The total score is the sum of the
scores 1–7 in the 20 items (range 20–140). Norm scores
are available for different patient groups and healthy people.
The CIS has also been successfully used in long-term survi-
vors of childhood cancer [26]. The CIS showed to have
good internal consistency and validity across studies and
could successfully discriminate between non-fatigued and
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fatigued groups and cut-off points for clinical levels of
fatigue have been developed [26, 122, 123].
Mental health
Psychological distress will be assessed using the Brief
Symptom Inventory (BSI) [124]. The BSI is a widely used
and well-validated instrument to screen the following nine
domains of distress: somatization, obsessive-compulsive
tendencies, interpersonal sensitivity, depression, anxiety,
aggression, phobic anxiety, paranoid ideation, and psych-
otic tendencies. Responses to all 53 items can be further
summarized in the Global Severity Index (GSI). For each
item, participants express how much they agree with a
statement describing the previous 7 days on a 5-point
Likert-scale ranging from 1 (not at all) to 5 (very much).
Scores from all scales will be transformed to T-scores
(mean = 50, SD = 10, range 0–100) according to the Ger-
man norm population [125]. A T-score of ≥63 on any scale
corresponds to the 90th percentile of the norm population
and indicates a risk for being at significant psychological
distress in this area (case rule) [125].
Personal history and clinical examination
A thorough personal history, study of the medical record
and clinical examination is performed in each participant,
with special emphasis on the cancer history, signs and
symptoms of cardio-metabolic, pulmonary or neurological
diseases, health behaviour, medical doctor visits, hospitaliza-
tions, and medications [126–128]. Symptoms, medical doc-
tor visits, hospitalizations and medications are updated after
6 and 12 months. Physical examination of the lungs, heart,
abdomen, joints, extremities, ears, mouth, lymph nodes and
a detailed neurological status are performed at baseline and
after 6 and 12 months. Vital parameters including heart rate
and blood pressure are taken at every visit. Tanner stadium
is assessed once at baseline and only repeated after 6 and
12 months if the participant is not fully mature at baseline
[129]. Socio-demographic characteristics are assessed by
questionnaire at baseline, health behaviours at baseline and
after 12 months, using standardized questions from the
Swiss Health Survey and the Swiss Census [126–128].
Adverse events and exercise related complications
Every adverse event including exercise related complica-
tions [130] whether or not causally related with the exercise
training will be monitored based on standardized proce-
dures and followed until resolved [131]. Each adverse event
is recorded in the REDCap database and classified based on
The Common Terminology Criteria for Adverse Events
(CTCAE) [131]. Serious adverse events are reported to the
sponsor and the responsible independent ethics committee.
An independent safety auditor of the University Children’s
Hospital Basel (UKBB) is monitoring patients’ safety
throughout the study period.
Participants who show an elevated blood pressure or a
pathological oral glucose tolerance test at baseline or
during a study visits, can enter/stay in the study, but are
referred to the family physician or a specialist to get the
appropriate treatment. In case of diabetes, the partici-
pant will enter the study once a stable condition is
reached but earliest after 3 months.
Participants at risk for cardiac late-effects due to cardio-
toxic childhood cancer therapy (anthracyclines and/or chest
radiation) can enter the study normally, but are recom-
mended to get a cardiac assessment with an adult
cardiologist according to recent recommendations [132].
Physical activity intervention (intervention group)
Survivors in the intervention group are asked to add at
least 2.5 h of intense physical activities per week. These
should include 30 min of strength building exercises and
2 h of aerobic exercises per week. Exercise bouts lasting
20 min or longer are counted towards the total weekly
training time. This “dose” of physical activity is based on
the international recommendations of healthy physical ac-
tivities from the Centre of Disease Control and Prevention
(CDC; www.cdc.gov) [133].
Based on the initial exercise test, general health status and
participant’s preferences and motivation, subjects of the
intervention group receive a counselling at the second visit
of the baseline assessment (T0b; Fig. 1, Additional file 2:
Table S1). A standardized approach is used to assess survi-
vors’ preferences with respect to physical activities, identify
possible barriers and determine the individual motivation to
start specific activities. Based on this assessment, individual-
ized physical activities are defined and implemented into the
participant’s daily life. Survivors of the intervention group are
also motivated to incorporate activities of moderate
intensities into daily life such as walking instead of driving or
climbing stairs instead of taking the escalator. Participants
are also advised to reduce inactive behaviour such as televi-
sion viewing, computer games, etc. with the aim of reducing
25% of their actual media time. The motivational interview is
performed by one of the project physiotherapists who have
been trained prior to the study.
For motivational reasons each survivor of the intervention
group is equipped with a step counter (pedometer, Model
Fitbug Air) and asked to document daily steps. Participants
keep a daily training log using a web-based platform with
individual anonymous logins. Data on 1) strenuous exercise
performed that day (type of exercise, duration), 2) step
counts (overall and aerobic steps), 3) media-related sedentary
time and sleeping hours, and 4) mood and well-being are
entered and graphically displayed to give the participants an
immediate feedback about their progress. The participants
receive a “reminder” message on his or her mobile phone or
via email if no entries are made for three consecutive days. If
there are no entries for a whole week, the survivor is
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contacted by phone by his “personal coach” (physiotherap-
ist). There are also scheduled phone contacts after 1, 2, 4, 5,
8 and 10 months of the intervention to discuss compliance,
motivation, and progress and to re-counsel the survivors on
their training plan. Training logs and physical activity
behaviour are checked and discussed during the clinic visits
(at months 3 and 6), and exercise counselling is repeated.
After the 1-year assessment, participants of the interven-
tion group can keep their step counters and will still have
access to the web-based training log to report and view their
activity data, but no further support is given from the re-
search team. A follow-up after 1–2 years off trial is planned
but this is not subject of the current study protocol.
Control group
The control population of this study is asked to keep its ac-
tivity level constant over the one-year study period. With this
study, we will be able to test the effect of additional physical
activity compared to a “normal” activity level. After the one-
year study period, participants of the control population have
the opportunity to receive the same personalized physical
activity counselling and motivational interview, but without
personal follow-up coaching. They also receive a step
counter and access to the same web-diary, which they can
use to follow their physical activity plan.
Compliance
Compliance of the participants is assessed by different means.
This will allow us to validate whether the aims of the inter-
vention and control arm have been maintained and to make
dose-response analyses for physical activity in this population.
Participants of the intervention group daily report the ped-
ometer steps and sports performed in the web-diary, they
are contacted immediately in case of non-compliance, they
have monthly telephone contacts with the physiotherapists,
and three-to-six-monthly assessment visits with the physi-
cians, physiotherapists and other staff. After the one-year
intervention, a structured interview is performed with the
participants of the intervention group to assess their opinion
on the intervention, their compliance, reasons for compli-
ance or non-compliance and readiness to continue the phys-
ical activity programme. Furthermore, at each study visit (3,
6, and 12 months), the retained steps of the pedometers over
2 weeks prior to the visits are (unknown to the participants)
downloaded and entered into the study database to assess
how accurate participants of the intervention group report
their daily steps in the web-diary.
Participants of the intervention and control group report
their actual activities at each visit (T3, T6, and T12) and we
objectively measure the activity levels at T6 and T12.
Blinding
With our physical activity intervention, it will not be pos-
sible to blind the study participants themselves, the project
physiotherapists, the project physicians and some of the
assessors. But wherever possible all other members of the
project team will be blinded for group allocation of the
participants, i.e. those who perform the DXA measurement,
the physical performance test, the blood analysis, the
quality check of the data in the database and the statistical
analysis.
Sample size
A study by Kriemler and colleagues using the same CVD
risk score showed a reduction in the z-score by 14% after a
1-year physical activity intervention in children and adoles-
cents [34]. Our population is older with a history of cancer,
intensive treatments and long hospitalisations. We there-
fore expect higher CVD risk in this population at baseline
and even greater changes after an intervention. To be con-
servative, this study is powered to detect a difference be-
tween the intervention and control group of 15% (no
change in the control group and 15% change in the inter-
vention group) after the 1-year intervention. For a power of
0.80 and a two-sided type 1 error probability of 0.05, 60
survivors with complete data are required in each study
arm. Assuming that 20% of participants will dropout or
have missing data, 75 survivors have to be recruited in each
arm. From the Swiss Childhood Cancer Registry we identi-
fied 4241 eligible 5-year survivors of whom about 1500
were diagnosed and treated in one of the three Swiss
Paediatric Oncology Group (SPOG) clinics of initial recruit-
ment (Basel, Lucerne, and Zurich) [3]. Therefore, with an
expected participation rate of 20% of the survivors con-
tacted and invited, we will reach a sufficient sample size.
Data analysis
Descriptive statistics will be used for clinical, sociodemo-
graphic and prognostic variables measured at baseline
(stratified by intervention and control group). We will use
frequencies and proportions with 95% confidence intervals
(CI) for categorical variables and mean with ±SD or 95% CI
(or median and range) for continuous variables. Descriptive
analysis of baseline characteristics will be performed as
soon as the baseline assessments are completed for all
participants. This cross-sectional analysis will inform about
the comparability of the treatment groups and the need for
adjustment of between treatment group comparisons.
Furthermore, baseline assessments will provide important
results about characteristics, health behaviours and health
status of long-term CCS in Switzerland. We will also
compare the distribution of baseline sociodemographic
characteristics to the Swiss Childhood Cancer Registry, to
estimate the representativeness of our sample.
The primary analysis will be conducted as intention-to-
treat analysis (ITT) for the primary outcome (change in
composite CVD score from T0 to T12). All participants
will be analysed in the group where they were originally
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allocated and missing data will be imputed by means of
last observation carried forward (LOCF) [134]. LOCF is
an appropriate procedure in this setting because it will
lead to more conservative effect estimates (i.e. towards the
null), because lost to follow-up is more likely to occur in
the intervention group (because of an intensive and time-
consuming programme) which is the group expected to
change (improve). Attempt will be done to follow up all
randomised participants, even if they withdraw from the
allocated treatment. If the parameters of the composite
CVD risk score are skewed, they will be transformed to
reach normal distribution for calculating the z-scores.
The secondary analyses include several steps: First, we
will do the same ITT analysis with appropriate means of
imputation of missing data for all the secondary outcomes.
Second, we will perform sensitivity analysis on the primary
and all secondary outcomes, including, a) complete data
(complete case analysis), i.e. observations with missing in-
formation on relevant variables will be dismissed; b) ana-
lysis of intermediate effects after 3 and 6 months of
intervention; c) dose-response analysis based on the actual
physical activities (min of vigorous physical activities per
week) or physical performance (VO2peak) during the
period of interest, independent of the group allocation;
and, d) per protocol analysis.
Per protocol analysis will include several analyses based
on the actual “treatment” that the participants adhered to
(independent of group allocation), first based on the re-
ported compliance and second based on the assumed
compliance. In the first analysis based on the reported
compliance, the following participants will be analysed as
being in the “intervention group”: participants randomized
into the intervention group who reported in the web-diary
to have reached at least 2/3 of the target physical activity
(addition of 100 min of moderate to vigorous physical ac-
tivities [MVPA]); and, participants who were randomized
to the control group but reported in the physical activity
questionnaires to have increased their physical activity
level by more than 30 min of extra MVPA per week
during the period of interest. The rest of the participants
will be analysed as being a “control”. The second analysis
of reported compliance will include only the participants
sufficiently compliant with the protocol that they were al-
located to. It will include those randomized into the inter-
vention group who completed at least 2/3 of training
volume (e.g. the addition of 100 min per week of vigorous
PA) and compare them to those randomized into the con-
trol group with no more than 30 min of extra vigorous PA
per week than at baseline during the period of interest.
The analysis on the assumed compliance will be done
according to the analyses of the reported compliance but
with participants being defined as compliant if they
reach an increase of ≥5% in VO2peak and/or ≥10% in
the ventilatory anaerobic threshold from baseline [135].
Model selection Depending on the type of endpoint,
mixed linear, logistic, Cox or Poisson regression will be
used. All models will include the variables used in the
adaptive randomization (age and former cancer diagnosis)
and we will test the model assumptions and model fit.
The models might be further adjusted for baseline values
and important prognostic factors such as sex, socio-
economic status, health-behaviours, treatments received,
or former treating hospital if we observe an unequal distri-
bution of important confounders between the treatment
and control group.
The analysis will be done with Stata Statistical Software
version 14 or newer (StataCorp LP, College Station, Texas,
USA) and R Statistics (R Core Team, Vienna, Austria,
www.R-project.org). A p-value <0.05 will be considered as
statistically significant. Primary and secondary analyses
will be performed when the data collection is finished for
all participants.
Publication policy
Because of the large variety of outcomes assessed, we in-
tend to publish the effect of the intervention on the differ-
ent outcomes in more than one paper. We intend to
publish the effect of the intervention on our primary out-
come (CVD risk score) and related single cardiovascular
disease risk factors, glycaemic control and body compos-
ition in a single paper (main paper). This publication will
also include the changes in physical fitness and physical
activity as well as the clinical status and safety endpoints.
Beside this, we intend to publish the effect of the interven-
tion in different papers of the following topics:
- Effect on bone health
- Effect on quality of life, mental health and well being
Results of the baseline assessments only and further in
depth research questions will be published in additional
papers of meaningful topics.
Discussion
It’s estimated that 1 in 800 young adults under the age of
35 years living in developed countries is a survivor of
paediatric cancer [2]. Unfortunately, studies have shown
that the vast majority of these survivors present with
chronic medical conditions such as cardiovascular and
pulmonary diseases, 2nd cancers, overweight, osteopor-
osis, or psychological distress, directly impacting their late
mortality, morbidity and quality of life [4, 7, 117, 136].
Physical activity and exercise have become a cornerstone
in the prevention and treatment of chronic diseases
including cancer, cardiovascular morbidity and mortality,
diabetes, osteoporosis, fatigue or increasing psychological
well-being [11, 16, 137–147] Even in palliative care, physical
activity seems to reduce the burden of cancer- or therapy-
related side effects [148]. Despite these striking evidences,
there is a lack of randomized, controlled exercise trials
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aiming to reduce cancer- and therapy-related sequelae in
paediatric cancer survivors, which may ultimately increase
life expectancy, decrease morbidity and lead to an improve-
ment in quality of life. This is especially important for child-
hood cancer survivors as these patients are young with a
long life in front of them.
Besides contributing to the body of scientific knowledge,
this randomized controlled trial will also use a novel
approach with a personalized and partially supervised
exercise intervention. The intervention is supported by
multiple tools such as web-based feedback, pedometers
and individually tailored counselling. With this approach,
we try to overcome barriers and low compliance that is a
major problem in the sustainability of intervention studies.
Moreover, the measurement of most major cardio-
metabolic risk factors and bone health and the inclusion
of patient important outcomes like quality of life and psy-
chological distress provide a complete picture.
Another new aspect is the precise measurement of
bone architecture including a broad battery of possible
determinants of osteoporosis or decreased bone mass in
CCS. This may shed more light on the single and com-
bined risk factors of increased bone fracture risk or
osteoporosis in this population and on the potential pre-
ventive approaches.
The planned physical activity intervention has the po-
tential to become an important pillar in the support of
the whole CCS population. The project will evaluate
whether a 1-year partially supervised program including
exercise counselling with motivational feedback in CCS
(aged 16 years and above) is able to reduce long-term se-
quelae and/or lifestyle-related diseases including but not
limited to cardiovascular and metabolic risks as well as
bone health, physical fitness, mental health, and quality
of life. If the program shall prove effective, the SURfit
material will become available to interested national and
international clinics that treat and/or follow-up child-
hood cancer patients to promote exercise in their CCS.
Additional files
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. Contains the SPIRIT
Checklist in its original template. The table lists all the recommended items
that should be addressed in a clinical trial study protocol and indicates the
page numbers where the respective item is described. (DOCX 65 kb)
Additional file 2: Table S1. Schedule of enrolment, interventions and
assessments within SURfit (DOCX 138 kb)
Additional file 3: Measures and methods within SURfit at different time
points. The table in Additional file 3 describes in detail the methods used
for each measurement in SURfit. It is an extension of the (Additional file 2:
Table S1) in the paper. (DOCX 81 kb)
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